Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

612
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
612
Tissue Transplantation01:24

Tissue Transplantation

832
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
832
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

289
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
289

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can FMN even the playing field? Mitochondrial FMN during hypothermic oxygenated perfusion to guide liver utilization.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

The Impact of Failed Deceased Donor Kidney Graft Longevity on Mortality.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same author

The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients.

Acta neurochirurgica·2026
Same author

Fractionated radiotherapy adjuvant to surgery of WHO-2 meningioma with and without gross total resection: a multicenter, retrospective cohort study of 1,452 patients.

Journal of neuro-oncology·2026
Same author

Stereotactic Body Radiation Therapy Facilitating Debulking Surgery in Metastatic VIPoma with Severe Diarrhea and Hypovolemic Shock.

The American journal of case reports·2025
Same author

Association of Transplant Rate Ratio, Waitlist Survival, and Post-Transplant Survival: Analysis of Scientific Registry of Transplant Recipients Metrics.

The Journal of surgical research·2025

Related Experiment Video

Updated: Jan 3, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K

Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.

Stanley L Liauw1, Sandra A Ham2, Lauren C Das3

  • 1Department of Radiation and Cellular Oncology.

Journal of the National Cancer Institute
|November 16, 2019
PubMed
Summary

Organ transplant recipients with prostate cancer face higher overall mortality but similar cancer-specific mortality. Active surveillance may be suitable for low-risk prostate cancer in these patients.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

4.2K

Related Experiment Videos

Last Updated: Jan 3, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

4.2K

Area of Science:

  • Oncology
  • Transplant Surgery
  • Geriatric Medicine

Background:

  • Organ transplantation necessitates immunosuppression, increasing cancer risk.
  • Prostate cancer patients with transplant history may receive aggressive treatment regardless of risk.
  • This study investigates prostate cancer outcomes in organ transplant recipients.

Purpose of the Study:

  • To compare prostate cancer-specific mortality (PCSM) and overall mortality (OM) in older men with and without a history of organ transplant.
  • To evaluate the impact of transplant status on treatment decisions and outcomes for nonmetastatic prostate cancer.

Main Methods:

  • Utilized SEER-Medicare data for 163,676 men aged 66+ with nonmetastatic prostate cancer.
  • Identified transplant recipients and matched them to non-transplant controls using propensity scores.
  • Employed Fine-Gray competing risk models to assess mortality differences.

Main Results:

  • A cohort of 620 transplant recipients was matched to 3100 controls.
  • Transplant recipients had significantly higher 10-year overall mortality (55.7% vs. 42.4%).
  • No significant difference in prostate cancer-specific mortality was observed between groups (6.0% vs. 7.6%).
  • Low-risk prostate cancer in transplanted men showed similar PCSM whether treated or untreated.

Conclusions:

  • Organ transplant is linked to increased overall mortality but not prostate cancer-specific mortality in older men.
  • Standard care, including active surveillance for low-risk disease, is appropriate for prostate cancer patients with transplant history.
  • Findings support individualized management based on cancer characteristics rather than solely transplant status.